DF Dent & Co. Inc. grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 512,077 shares of the life sciences company’s stock after buying an additional 11,012 shares during the quarter. Illumina accounts for about 3.2% of DF Dent & Co. Inc.’s investment portfolio, making the stock its 6th biggest position. DF Dent & Co. Inc.’s holdings in Illumina were worth $143,018,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Jennison Associates LLC grew its stake in Illumina by 4.5% in the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after purchasing an additional 185,745 shares in the last quarter. Fred Alger Management Inc. grew its stake in Illumina by 21.4% in the second quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after purchasing an additional 137,302 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Illumina by 5.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock worth $168,863,000 after purchasing an additional 31,985 shares in the last quarter. Millennium Management LLC grew its stake in Illumina by 219.8% in the second quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock worth $153,318,000 after purchasing an additional 377,283 shares in the last quarter. Finally, Federated Investors Inc. PA grew its stake in Illumina by 4.1% in the second quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock worth $143,167,000 after purchasing an additional 20,324 shares in the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Mostafa Ronaghi sold 7,500 shares of the stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $288.89, for a total transaction of $2,166,675.00. Following the completion of the sale, the senior vice president now owns 78,496 shares in the company, valued at approximately $22,676,709.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 1,346 shares of the stock in a transaction on Friday, September 7th. The shares were sold at an average price of $345.14, for a total value of $464,558.44. Following the sale, the director now owns 7,139 shares of the company’s stock, valued at approximately $2,463,954.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,537 shares of company stock valued at $13,779,035. 0.54% of the stock is owned by company insiders.

Illumina stock opened at $355.91 on Friday. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. The firm has a market cap of $51.42 billion, a price-to-earnings ratio of 88.98, a P/E/G ratio of 2.90 and a beta of 0.97. Illumina, Inc. has a twelve month low of $196.00 and a twelve month high of $357.93.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.32. The company had revenue of $830.00 million during the quarter, compared to analyst estimates of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. Illumina’s revenue was up 25.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. analysts anticipate that Illumina, Inc. will post 5.46 earnings per share for the current fiscal year.

Several brokerages recently issued reports on ILMN. Barclays increased their price objective on Illumina from $300.00 to $350.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 31st. JPMorgan Chase & Co. increased their price objective on Illumina to $350.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 31st. Cowen increased their price objective on Illumina from $275.00 to $315.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $350.00 price objective on shares of Illumina in a research note on Tuesday, July 31st. Finally, Bank of America increased their price objective on Illumina from $345.00 to $370.00 and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $308.25.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Do You Need a Fiduciary?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.